Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AssigneeAlkermes, Inc.
InventorPhillip M. Friden
Life of this patent
Estimating the term…
Abstract
The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.
Claims27
A method for delivering a therapeutically effective amount of nerve growth factor across the blood brain barrier of a mammal comprising administering antibody-nerve growth factor conjugate to the mammal under conditions whereby said conjugate binds to transferrin receptors on brain capillary endothelial cells and nerve growth factor is transported across the blood brain barrier of the mammal in a pharmaceutically active form and in a therapeutically effective amount.
A method for treating a neurological disorder in a mammal comprising administering of a therapeutically effective amount of an antibody-nerve growth factor conjugate to the mammal under conditions whereby said conjugate binds to transferrin receptors on brain capillary endothelial cells and nerve growth factor is transported across the blood brain barrier in a pharmaceutically active form which thereby alleviates the neurological disorder.
A method for supporting the growth of cholinerigc neurons in the brain of a mammal comprising administering of an effective amount of an antibody-nerve growth factor conjugate to the mammal under conditions whereby said conjugate binds to transferrin receptors on brain capillary endothelial cells and nerve growth factor is transported across the blood brain barrier in a physiologically active form which thereby supports the growth of cholinergic neurons.
An antibody-nerve growth factor conjugate wherein said conjugate is bindable to transferrin receptors on brain capillary endothelial cells.
A pharmaceutical composition comprising an antibody-nerve growth factor conjugate and a pharmaceutically acceptable carrier wherein said conjugate is bindable to transferrin receptors on brain capillary endothelial cells.
Dependencies are inferred from the claim text.